Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0007570
Disease: Celiac Disease
Celiac Disease 		0.300 Biomarker disease CTD_human Celiac disease biomarkers identified by transcriptome analysis of small intestinal biopsies. 30097691 2018
CUI: C0021843
Disease: Intestinal Obstruction
Intestinal Obstruction 		0.300 Biomarker disease CTD_human Multiple apical plasma membrane constituents are associated with susceptibility to meconium ileus in individuals with cystic fibrosis. 22466613 2012
CUI: C1859047
Disease: CYSTIC FIBROSIS MODIFIER 1
CYSTIC FIBROSIS MODIFIER 1 		0.300 Biomarker disease CTD_human Multiple apical plasma membrane constituents are associated with susceptibility to meconium ileus in individuals with cystic fibrosis. 22466613 2012
CUI: C0021390
Disease: Inflammatory Bowel Diseases
Inflammatory Bowel Diseases 		0.200 Biomarker group RGD Experimental colitis: decreased Octn2 and Atb0+ expression in rat colonocytes induces carnitine depletion that is reversible by carnitine-loaded liposomes. 17065219 2006
CUI: C0036216
Disease: Sarcoma, Experimental
Sarcoma, Experimental 		0.200 Biomarker disease RGD Stimulation of expression of the intestinal glutamine transporter ATB0 in tumor-bearing rats. 17006743 2006
CUI: C0001122
Disease: Acidosis
Acidosis 		0.200 Biomarker phenotype RGD Stimulation of intestinal glutamine absorption in chronic metabolic acidosis. 15300171 2004
CUI: C0010674
Disease: Cystic Fibrosis
Cystic Fibrosis 		0.060 AlteredExpression disease BEFREE Among the most strongly down-regulated genes are the FXR targets Fgf15 and Nr0b2, the PPARα target Pdk4, and the PXR target Ces2a, whereas expression of the CF modifier gene Slc6a14 was strongly increased. 31251978 2020
CUI: C0010674
Disease: Cystic Fibrosis
Cystic Fibrosis 		0.060 GeneticVariation disease BEFREE Using CFBE41o cells, we showed that the positive SLC6A14 effect was mainly dependent on the nitric oxide (NO) synthase activity, nitrogen oxides, including NO, and phosphorylation by protein kinase G. These finding were confirmed in CF-HBE, as inducible NO synthase inhibition abrogated the functional interaction between SLC6A14 and pharmacological corrected F508del-CFTR. 31189070 2019
CUI: C0010674
Disease: Cystic Fibrosis
Cystic Fibrosis 		0.060 GeneticVariation disease BEFREE The purpose of the current work was to determine the biological role of <i>Slc6a14,</i> by disrupting its expression in CF mice bearing the major mutation, F508del. 30004386 2018
CUI: C0010674
Disease: Cystic Fibrosis
Cystic Fibrosis 		0.060 GeneticVariation disease BEFREE Association of clinical severity of cystic fibrosis with variants in the SLC gene family (SLC6A14, SLC26A9, SLC11A1 and SLC9A3). 28756021 2017
CUI: C0010674
Disease: Cystic Fibrosis
Cystic Fibrosis 		0.060 Biomarker disease BEFREE Regions on chr3q29 (MUC4/MUC20; P=3.3 × 10(-11)), chr5p15.3 (SLC9A3; P=6.8 × 10(-12)), chr6p21.3 (HLA Class II; P=1.2 × 10(-8)) and chrXq22-q23 (AGTR2/SLC6A14; P=1.8 × 10(-9)) contain genes of high biological relevance to CF pathophysiology. 26417704 2015
CUI: C0010674
Disease: Cystic Fibrosis
Cystic Fibrosis 		0.060 Biomarker disease BEFREE We sought to determine whether SLC26A9, SLC9A3 and SLC6A14, that contribute to meconium ileus in CF, are pleiotropic for other early-affecting CF co-morbidities. 24057835 2014
CUI: C0028754
Disease: Obesity
Obesity 		0.030 GeneticVariation disease BEFREE In conclusion, these data confirm an association of the SLC6A14 gene locus with obesity. 15331564 2004
CUI: C0028754
Disease: Obesity
Obesity 		0.030 Biomarker disease BEFREE The SLC6A14 gene is an interesting novel candidate for obesity because it encodes an amino acid transporter, which potentially regulates tryptophan availability for serotonin synthesis and thus possibly affects appetite control. 14660752 2003
CUI: C0028754
Disease: Obesity
Obesity 		0.030 GeneticVariation disease BEFREE Do allelic variants of SLC6A14 predispose to obesity? 14660737 2003
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.020 AlteredExpression group BEFREE Plasma membrane transporter SLC6A14 transports all neutral and basic amino acids in a Na/Cl - dependent way and it is up-regulated in many types of cancer. 31326539 2019
CUI: C0024115
Disease: Lung diseases
Lung diseases 		0.020 Biomarker group BEFREE Using the SS we integrated the lung disease association locus with eQTLs from nasal epithelia of 63 CF participants and demonstrated evidence of colocalization with airway-specific regulation of SLC6A14 (p = 2.3x10(-4)). 30807572 2019
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma 		0.020 Biomarker disease BEFREE Survival analysis of TCGA data and clinical data suggested that TMC7, TMPRSS4, SCEL, SLC2A1, CENPF, SERPINB5 and SLC6A14 can be potential biomarkers for the prognosis of PC. 30639415 2019
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.020 AlteredExpression group BEFREE Plasma membrane transporter SLC6A14 transports all neutral and basic amino acids in a Na/Cl - dependent way and it is up-regulated in many types of cancer. 31326539 2019
CUI: C1335302
Disease: Pancreatic Ductal Adenocarcinoma
Pancreatic Ductal Adenocarcinoma 		0.020 AlteredExpression disease BEFREE Survival analysis unveiled that the high expression levels of SLC6A14, GALNT5 and TSPAN1 may correlate with the poor prognosis while high expression levels of IAPP may contribute to a better prognosis in patients with PAAD. 31731384 2019
CUI: C2939175
Disease: Meconium ileus
Meconium ileus 		0.020 Biomarker disease BEFREE The associated modifier loci colocalized with expression quantitative trait loci (eQTLs) for ATP12A (p = 3.35x10(-8)), SLC6A14 (p = 1.12x10(-10)) and SLC26A9 (p = 4.48x10(-5)) in the pancreas, even though meconium ileus manifests in the intestine. 30807572 2019
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.020 Biomarker group BEFREE The present review primarily focuses on one particular amino acid transporter, SLC6A14 (also known as ATB<sup>0,+</sup>), with regard to its relevance to specific diseases, including cancer, and the molecular mechanisms underlying the disease-related alterations in the expression of the transporter. 29204754 2017
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.020 Biomarker group BEFREE The present review primarily focuses on one particular amino acid transporter, SLC6A14 (also known as ATB<sup>0,+</sup>), with regard to its relevance to specific diseases, including cancer, and the molecular mechanisms underlying the disease-related alterations in the expression of the transporter. 29204754 2017
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma 		0.020 AlteredExpression disease BEFREE The expression of amino acid transporters in pancreatic cancer was analysed using publicly available microarray datasets, and the findings with the transporter SLC6A14 were validated by mRNA and protein analysis. 27747870 2016
CUI: C1335302
Disease: Pancreatic Ductal Adenocarcinoma
Pancreatic Ductal Adenocarcinoma 		0.020 Biomarker disease BEFREE Transcriptomic and Immunohistochemical Profiling of SLC6A14 in Pancreatic Ductal Adenocarcinoma. 26106611 2015